Antibody that binds to vegf and il-1beta and methods of use
US-2020199214-A1 · Jun 25, 2020 · US
Antibody that binds to VEGF-A and ANG2 and methods of use
US12522653B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12522653-B2 |
| Application number | US-202318339713-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2023 |
| Priority date | Sep 4, 2020 |
| Publication date | Jan 13, 2026 |
| Grant date | Jan 13, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
First claim
Opening claim text (preview).
The invention claimed is: 1 . An isolated single nucleic acid encoding a Fab heavy chain and a Fab light chain of a Fab fragment that binds to human vascular endothelial growth factor A (VEGF-A) and to human angiopoietin-2 (ANG2), wherein the Fab heavy chain comprises a VH amino acid sequence of SEQ ID NO: 19 and the Fab light chain comprises a VL amino acid sequence of SEQ ID NO: 20. 2 . A host cell comprising an expression vector comprising the nucleic acid of claim 1 . 3 . A method of producing a Fab fragment that binds to human VEGF-A and to human ANG2 comprising culturing the host cell of claim 2 so that the Fab fragment is produced. 4 . The method of claim 3 , wherein the host cell is a CHO cell. 5 . An isolated single nucleic acid encoding a Fab heavy chain and a Fab light chain of a Fab fragment that binds to human VEGF-A and to human ANG2, wherein the Fab heavy chain amino acid sequence is SEQ ID NO: 24 and the Fab light chain amino acid sequence is SEQ ID NO: 25. 6 . A host cell comprising an expression vector comprising the nucleic acid of claim 5 . 7 . A method of producing an antibody a Fab fragment that binds to human VEGF-A and to human ANG2 comprising culturing the host cell of claim 6 so that the Fab fragment is produced. 8 . The method of claim 7 , wherein the host cell is a CHO cell. 9 . An first isolated nucleic acid encoding a Fab heavy chain of a Fab fragment and a second isolated nucleic acid encoding a Fab light chain of a Fab fragment, wherein the Fab fragment binds to human vascular endothelial growth factor A (VEGF-A) and to human angiopoietin-2 (ANG2), wherein the Fab heavy chain comprises a VH amino acid sequence of SEQ ID NO: 19 and the Fab light chain comprises a VL amino acid sequence of SEQ ID NO: 20. 10 . A host cell comprising an expression vector comprising the first isolated nucleic acid and the second isolated nucleic acid of claim 9 . 11 . A method of producing a Fab fragment that binds to human VEGF-A and to human ANG2 comprising culturing the host cell of claim 10 so that the Fab fragment is produced. 12 . The method of claim 11 , wherein the host cell is a CHO cell. 13 . An first isolated nucleic acid encoding a Fab heavy chain of a Fab fragment and a second isolated nucleic acid encoding a Fab light chain of a Fab fragment, wherein the Fab fragment binds to human vascular endothelial growth factor A (VEGF-A) and to human angiopoietin-2 (ANG2), wherein the Fab heavy chain comprises a VH amino acid sequence of SEQ ID NO: 24 and the Fab light chain comprises a VL amino acid sequence of SEQ ID NO: 25. 14 . A host cell comprising an expression vector comprising the first isolated nucleic acid and the second isolated nucleic acid of claim 13 . 15 . A method of producing a Fab fragment that binds to human VEGF-A and to human ANG2 comprising culturing the host cell of claim 14 so that the Fab fragment is produced. 16 . The method of claim 15 , wherein the host cell is a CHO cell.
Assignees
Inventors
Classifications
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Complementarity determining region [CDR] · CPC title
Fab or Fab' · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12522653B2 cover?
- The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).